Among the group’s current objectives is the development and validation of tissue diagnostic tests to adjust the target patient population of antibody drug conjugates. Applying quantitative mass spectrometry to precision oncology, and improving stratification of patients for FGFR pathway inhibition through the development of combined preselection approaches. In addition, expanding the catalogues of molecular tests accredited by ISO15189.

Visit the research group’s page